Upstream Bio plans Phase 3 trials in severe asthma and CRSwNP in Q1 2027
Upstream Bio reported Q3 financial results and highlighted its continued clinical progress. The company plans to initiate key Phase 3 trials in Q1 2027, reflecting a strategic shift toward advancing its late-stage immunological therapies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed